Witty’s Bonus Slashed As GSK Recovers From China Scandal
This article was originally published in PharmAsia News
Still learning lessons from 2013's bribery scandal and subsequent investigations in China, GlaxoSmithKline's CEO Sir Andrew Witty had his annual bonus for the past year slashed in half.
You may also be interested in...
In her first address as CEO, Emma Walmsley has shocked the market with a long list of changes for GSK, including a total makeover of the group's pharma unit. As a result, more than 30 R&D programs will be getting the axe and a 2011 commercialization partnership with Johnson & Johnson is on its way to the gallows.
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.